Research programme: topical NSAID - Milestone Pharmaceuticals
Latest Information Update: 01 Apr 2011
At a glance
- Originator Milestone Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Actinic keratosis; Exanthema; Osteoarthritis; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis
Most Recent Events
- 09 Aug 2007 Preclinical trials in Exanthema in Canada (Topical)
- 09 Aug 2007 Preclinical trials in Rheumatoid arthritis in Canada (Topical)
- 09 Aug 2007 Preclinical trials in Psoriasis in Canada (Topical)